Axa’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Axa’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-101,816	Closed	-$2.73M	–	1250
2022 Q1	$2.73M	Buy	101,816 +1	+0%	+$34	0.01%	777
2021 Q4	$4.86M	Buy	101,815 +1,217	+1%	+$54.4K	0.01%	671
2021 Q3	$6.68M	Buy	100,598 +3,702	+4%	+$264K	0.02%	604
2021 Q2	$7.56M	Buy	96,896 +15,390	+19%	+$1.14M	0.02%	590
2021 Q1	$7.71M	Buy	81,506 +1,510	+2%	+$180K	0.02%	578
2020 Q4	$9.75M	Sell	79,996 -11,470	-13%	-$1.26M	0.03%	530
2020 Q3	$7.99M	Sell	91,466 -40,151	-31%	-$2.8M	0.03%	523
2020 Q2	$8.5M	Sell	131,617 -12,809	-9%	-$739K	0.03%	474
2020 Q1	$6.45M	Sell	144,426 -8,143	-5%	-$432K	0.03%	458
2019 Q4	$9.5M	Buy	+152,569	New	+$7.26M	0.04%	461

Other funds holding TPTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Axa's TPTX Position: Q2 2022 in Review

Axa sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q2 2022, closing a stake of 101,816 shares — an estimated $2.73M sold.

Axa first reported a position in TPTX in Q4 2019 and held it in 10 quarters. The position peaked at $9.75M in Q4 2020. 208 funds tracked by Wall St. Rank hold TPTX as of Q2 2022.

Axa reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Axa sold 101,816 Turning Point Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $2.73M.
Axa first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q4 2019 and held it in 10 quarters.
Axa's Turning Point Therapeutics, Inc. Common Stock position peaked at $9.75M in Q4 2020.
208 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Axa's 13F filing for Q2 2022, filed 15 Aug 2022.